rethinkTHC Search
Menu
Study breakdown

Review of cannabinoid treatments for autism spectrum disorder symptoms

Mini ReviewModerate evidence
The takeaway

Uncontrolled studies of CBD-rich cannabis extracts showed improvements in autism-related symptoms, but placebo-controlled trials have produced mixed results, and researchers recommend waiting for ongoing trials before adopting CBD for ASD.

Parents of children with ASD exploring cannabinoid options, pediatric neurologists, clinical trial researchers

Mixed results in placebo-controlled trials

What the researchers found

Uncontrolled case series documented improvements in both core ASD symptoms and behavioral challenges with CBD-rich cannabis extracts. However, placebo-controlled studies of CBD-rich extracts and pure CBD showed mixed efficacy results. Studies demonstrated relatively high safety and tolerability.

Why it matters

ASD affects approximately 3% of school-age children with no approved treatment for core symptoms. Current medications (risperidone, aripiprazole) only address irritability with limited effectiveness and common side effects. Families increasingly seek cannabinoid alternatives.

The numbers in context

ASD affects ~3% of school-age children. Only risperidone and aripiprazole are approved for ASD-related irritability. Placebo-controlled studies included CBD-rich cannabis extracts, pure CBD, and studies in Fragile X syndrome.

How the study worked

Mini-review summarizing existing literature and ongoing clinical trials of cannabinoid treatments for ASD, including uncontrolled case series and placebo-controlled studies of CBD-rich extracts and pure CBD.

What this study cannot tell us

Uncontrolled studies are susceptible to placebo and expectancy effects, particularly in behavioral conditions. Placebo-controlled trials are few and showed mixed results. Different formulations (pure CBD vs. CBD-rich extracts) may have different effects.

How to read the evidence

Mini-review of limited clinical trial evidence, with uncontrolled studies showing benefits but placebo-controlled trials producing mixed results.

When this study was published

2024 review of cannabinoid treatment evidence for ASD

The bigger picture

The gap between parental enthusiasm for CBD in ASD and the mixed clinical evidence mirrors patterns seen with other conditions where traditional treatments fall short. The relatively good safety profile may justify continued investigation even without proven efficacy.

Questions still open

  • Will ongoing placebo-controlled trials clarify whether CBD benefits core ASD symptoms? Does CBD-rich whole-plant extract work differently than pure CBD for ASD?

Common questions

Is CBD approved for treating autism?
No. No cannabinoid treatment is approved for ASD. Current evidence from placebo-controlled trials is mixed, and researchers recommend waiting for results from ongoing clinical trials.
Is CBD safe for children with autism?
The studies reviewed showed relatively high safety and tolerability, but long-term safety data in children with ASD is limited. Any use should involve medical supervision.

Read the original research

Cannabinoid treatment for the symptoms of autism spectrum disorder.

Expert opinion on emerging drugs, 29(1), 65-79

Citation

Aran, Adi; Cayam Rand, Dalit. (2024). Cannabinoid treatment for the symptoms of autism spectrum disorder.. Expert opinion on emerging drugs, 29(1), 65-79. https://doi.org/10.1080/14728214.2024.2306290

Explore the wider topic